Regentis Biomaterials

Regentis' GelrinC Demonstrates Near-Complete Cartilage Repair in 24-Month Phase II Study Using Quantitative MOCART Assessment

- Regentis Biomaterials published peer-reviewed data in Cartilage journal showing GelrinC achieved a mean MOCART score of 88.8 out of 100 at 24 months, indicating near-complete structural cartilage repair. - The company became the first to use MOCART as a predefined endpoint in cartilage repair clinical trials, with FDA acceptance of this objective, quantitative imaging-based assessment approach. - GelrinC demonstrated superior performance with osteochondral lesions achieving 94 MOCART score and chondral lesions reaching 86.8, showing ongoing tissue maturation toward hyaline-like cartilage. - The hydrogel implant is currently in a pivotal Phase III FDA study with over 50% enrollment completed, while already holding CE Mark approval in Europe.